Corbus Pharmaceuticals (CRBP) PT Lowered to $54 at Oppenheimer
Tweet
Share
E-mailGet Alerts CRBP Hot Sheet
Price: $8.31 +0.61%
Rating Summary:
12 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 1 | Down: 2 | New: 2
Rating Summary:
12 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 1 | Down: 2 | New: 2
Join SI Premium – FREE
Oppenheimer analyst Jeff Jones lowered the price target on Corbus Pharmaceuticals (NASDAQ: CRBP) to $54.00 (from $57.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Morgan Stanley Upgrades QIAGEN NV (QIA:GR) (QGEN) to Overweight
- Morgan Stanley Upgrades Demant A/S (DEMANT:DC) (WILYY) to Overweight
- Siemens Healthineers (SHL:GR) (SEMHF) PT Lowered to EUR37 at Morgan Stanley
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
